CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187
http://doi.org/10.5281/zenodo.4387783

Avalable online at: http://www.iajps.com *Research Article*

ASSESSING THE ASSOCIATION WITH EGF POLYMORPHISM AND HCC IN HEPATITIS C (HCV) PATIENTS

[1]Muhammad Zakria, [2]Khalid Hussain, [3]Shumaila Ahmed Khan

[1]Medical Officer, THQ Hospital Khar Fort Munro

[2]Basic Health Unit Karam Pur Kher Pur Tamewali Bahawalpur

[3]Polyclinic Hospital Islamabad

Article Received: October 2020 **Accepted:** November 2020 **Published: December** 2020

Abstract:

Aim: *Hepatocellular carcinoma is the sixth most ordinary tumor in world. In Pakistan, its repeat has expanded because of the viral sickness hepatitis C. Epidermal development viewpoint assumes a significant function in the recuperation of hepatocytes and has accepted a part in the danger of movement. Single nucleotide polymorphism (SNP) of genotype G/G has been related with an expanded danger of HCC arrangement. The motivation behind this survey was to examine the connection between EGF polymorphism and HCC in HCV cases.*

Methods: *Our current research was conducted at Lahore General Hospital, Lahore from March 2019 to February 2020. Routine testing for cirrhosis of the liver and HCC, just as EGF genotyping were performed on two sets; cases having HCV-associated cirrhosis and cases having once again tried HCC for cirrhosis, while reference set accomplished EGF genotyping.*

Results: *EGF 63*G evaluation polymorphism was otherworldly in HCC cases. G/G had highest Center comparative with the A/An and A/G genotypes, through tremendous quantifiable centrality among sets dissected in entirety and consistency ($p < 0.0002$).*

Conclusion: *The quality polymorphism of EGF 62*G was related to the subjective idea of HCC. Likewise, the general blend of EGF stayed distinguished through the G/G genotype.*

Key words*: Association EGF Polymorphism, HCC, HCV Patients.*

Corresponding author:

Muhammad Zakria,

Medical Officer, THQ Hospital Khar Fort Munro

QR code

Please cite this article in press Muhammad Zakria et al., ***Assessing The Association With EGF Polymorphism And HCC In Hepatitis C (HCV) Patients****., Indo Am. J. P. Sci, 2020; 07(12).*

INTRODUCTION:

Hepatocellular carcinoma is 6th maximum mutual malignant disease universal and is considered the leading cause of death from long-term liver disease, affecting approximately one million patients per year worldwide with a frequency equivalent to death degree [1]. In Pakistan, about 5.8% of cases with long-lasting liver infections had HCC, furthermore HCC affects 71.49% of liver malignancies; their onset is owing to cirrhosis which is therefore a confounding of HCV. Pakistan has an exceptionally high occurrence of HCV, only about 6 million people and HCV viremia was counted as 4.4%. HCC has different etiologies, for example, the incessant contamination of hepatitis B and C, alcohol abuse, and many other etiological elements [2]. Abnormal joint quality, epigenetic changes, and chromosomal abnormalities imply significant work in the growth of HCC, though; atomic system is not yet strong [3]. Lately, numerous signing pathways, particularly those that manage physiological procedures, such as the development, separation, relocation, apoptosis and angiogenesis of tumour cells, have been examined in the development of HCC, for example, the epidermal development factor (EDF) signaling pathway [4]. In 1963, it was known that human EGF animated the multiplication and separation of epidermal and epithelial tissues by acting as an authority on the EGF receptor (EGFR). In mice, overexpression of human EGF improves the advancement of HCC. EGF quality polymorphism were related through numerous human distortions, counting HCC [5].

METHODOLOGY:

Our current research was conducted at Lahore General Hospital, Lahore from March 2019 to February 2020. Routine testing for cirrhosis of the liver and HCC, as well as EGF genotyping were performed on two sets; cases having HCV-connected cirrhosis and cases having afresh tested HCC for cirrhosis, whereas reference set achieved EGF genotyping. Fifty healthy, age- and sex-coordinated subjects were incorporated as a reference (Group III) [One control subject per case from the HCC family of understanding that was case-coordinated by sex and age (within five years)]. The investigation agreement remained accepted through moral logic panel of the National Hematology and Tropical Medicine Research Institute. This review was done according to the rules of the Declaration of Helsinki and its corrections. Compound assent was obtained from completely cases before preliminary this investigation. Cases remained divided into 2 sets, Set I that comprised 60 cases through HCV-related cirrhosis in addition Set II which encompassed 54 cases through recently tested HCC with HCV-related cirrhosis. Cases through additional malignancies of the liver, metastatic liver illness, intense and prolonged hepatitis, hepatic immune system problems, hereditary liver infections, liver illness other than HCV and a history of HCC remained not allowed.



Figure 1: Epidermal development aspect genotypes supply amongst studied sets:

Measurable test:

The information collected was broken down using SPSS (SPSS Inc, Chicago, ILL Company) Adaptation 23 programming. Direct information was entered as a number and rate, while quantitative information was entered as a mean and standard deviation. Examination of the constant information between multiple collections was done using a one-way ANOVA for parametric information and the Kruskal-Wallis test for non-parametric information through

post-tests (Turkey and Dunn test, individually). The Chi-square trial was applied for the examination amongst categorical information. The estimate P < 0.06 was considered to be noteworthy.



Figure 2: Epidermal development aspect serum level in diverse EGF genotypes of researched sets.

RESULTS:

Our review covered 160 respondents, cirrhotic gathering (Set I) (29 men and 24 women), their ages ranged from 41 to 68 years (mean age: 57.37 ± 7 years).519 years), the HCC set (Set II) (33 men and 19 women) were between 46 and 76 years of age (mean age: 59.63 ± 7.55 years) and the reference group (Group III) (31 males and 19 females) were between 44 and 69 years of age (mean age: 58.49 ± 7.232 years). There were irrelevant contrasts between all groups considered with respect to age and sex (P-esteem 0.218 and 0.6956, individually). For the EGF polymorphism, 3 genotypes, An/An, A/G and G/G, were identified in the three meetings considered. The An/A genotype was increasingly leading in reference group. The A/G genotype was increasingly predominant in cirrhotic set, whereas G/G genotype was progressively predominant in the HCC set. The correlation between the clusters examined with respect to the sum and level of EGF genotypes remained factually remarkable (P-esteem < 0.0002) (Table 1) (Figure 1). Examining convergence of FGE in each genotype for the three groups, it was found that there were critical contrasts in the attentiveness of FGE between the three genotypes in each group examined. The G/G claimed the highest focus when contrasted through the An/An and A/G genotypes in the patient groups, whereas in reference set here remained an unimportant measurable distinction between A/G and G/G with respect to the level of EGF (Figure 2) (Table 2).

Table 1 Comparison between the studied groups regarding number and percentage of epidermal growth factor genotypes.

EGF genotypes		Group I (Cirrhotic group) (*N* = 50)	Group II (HCC group) (*N* = 50)	Group III (Control group) (*N* = 50)	*P**
A/A genotype	No	7	3	42	<0.0001*
	%	14%	6%	84%	
A/G genotype	No	35	5	6	
	%	70%	10%	12%	
G/G genotype	No	8	42	2	
	%	16%	84%	4%	

*P**: *P*-value.



Figure 2 Epidermal growth factor serum level in different EGF genotypes of the studied groups.

Table 2 Comparison between the studied groups regarding epidermal growth factor level in different EGF genotypes.

EGF level	A/A genotype; Mean ± SD (Range) (Median)	A/G genotype; Mean ± SD (Range) (Median)	G/G genotype; Mean ± SD (Range) (Median)	*P*- value	Post-test	
Group I (Cirrhotic group) (No=50)	111.43 ± 11.802 (94-128) (114)	208.49 ± 32.866 (139-258) (219)	270.13 ± 39.223 (190-303) (285.5)	> 0.0001 *	P1	> 0.001 *
					P2	> 0.001 *
					P3	> 0.001 *
Group II (Hepatocellular carcinoma group) (No=50)	103.67 ± 9.609 (95-114) (102)	187.6 ± 23.891 (152-211) (199)	318.33 ± 43.559 (237-404) (325)	> 0.0001 *	P1	> 0.05
					P2	> 0.001 *
					P3	> 0.001 *
Group III (Control group) (No=50)	106.93 ± 8.019 (85-130) (106)	202.17 ± 9.704 (189-214) (202)	254.5 ± 14.849 (244-265) (254)	> 0.0001 *	P1	> 0.001 *
					P2	> 0.05 *
					P3	> 0.05

P1: group A/A vs. A/G; P2: group A/A vs. G/G ; P3: group A/G vs. G/G* Significant.

DISCUSSION:

Epidermal growth factor stimulates the development and separation of harmful cells, just as one would expect from epithelial cells. EGF appears to improve malignant tumour of the lungs, chest, colon and bladder. In mice, high-quality joint profiles examining normal and threatening liver tissue demonstrated the autocrine system for EGF in HCC [6]. A few unreflect tests are underway that reinforce the link between HCV and EGF. The passage of HCV cells is promoted by an instrument interposed by the EGFR. The relationship between EGF polymorphism and the danger of creating HCC was first revealed by Tanabe et al 2009 from two case-control studies and demonstrated that in cases through alcoholic cirrhosis and hepatitis C-related cirrhosis, the EGF 61*G allele is exceptionally related to the enlarged danger of HCC in G/G and A/G genotype patients, where cirrhotic G/G and A/G genotype patients had an overlap of 5 and 3.5 to create HCC, separately in An/A genotype patients and in contrasting genotype cases [7]. Those outcomes are consistent through current research, which displayed that G/G genotype was the most common genotype in HCC patients (85% of our HCC cases), followed by the A/G genotype in only 11%. The A/G genotype was most prevalent in the cirrhotic cases (71% of cirrhotic cases), while the An/A genotype was most predominant in reference group (85% of controls) [8]. These results demonstrate that the G allele may have an important part in hepatocarcinogenesis, while the An/A genotype may have a defensive role. Yuan et al 2015 demonstrated that in non-Asian Los Angeles residents, patients with the G allele had a higher risk of HCC when contrasted and the A/A genotype significantly more after alteration of various HCC risk factors.23Yoshiya et al 2016 led a review study of 145 cases and found that G/G remained available in 71 patients (49.8%), A/G in 57 (41.8%), and An/A in 18 (12.5%) [9]. Contrary to our outcomes, Qi et al 2010 certified that here remained not any relationship between rs4444924 EGF and HCC in Chinese cases with a long-lasting HCV disease. The studies show that relationship among EGF rs4444924 in addition danger of HCC remains still questionable and uncertain. The current research might be owing to certain realities, for example, assorted ethnic variety, control choice, and limited choice of example size [10].

CONCLUSION:

Finally, in this review, the FGC 62*G quality polymorphism was related to the danger of HCC. Added to this, the extended convergence of EGF was related to the G/G genotype.

REFEERENCES:

1. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid

opening in the new-born animal. *J Biol Chem* 1962; **237**: 1555-1562. [PMID: 13880319]
2. Carpenter G, Cohen S. Epidermal growth factor. *Annu Rev Biochem* 1979; **48**: 193-216. [DOI: 10.1146/annurev.bi.48.070179.001205]
3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality and survival trends in the United States from 1975 to 2005. *J Clin Oncol* 2009; **27 (9)**: 1485-1491. [DOI:10.1200/JCO.2008.20.7753]
4. Holah NS, El-Azab DS, Aiad HA, Sweed DM. Hepatocellular carcinoma in Egypt: epidemiological and histopathological properties. *Menoufia Medical Journal* 2015; **28**: 718-724. [DOI: 10.4103/1110-2098.167895]
5. Zhong JH, You XM, Gong WF, Ma L, Zhang Y, Mo QG, Wu LC, Xiao J, Li LQ. Epidermal Growth Factor Gene Polymorphism and Risk of Hepatocellular Carcinoma: A Meta-Analysis. *PLoS ONE* 2012; **7 (3)**: e32159. [DOI:10.1371/journal.pone.0032159]
6. Suenaga M, Yamada S, Fujii T, Fuchs BC, Okumura N, Kanda M, Kobayashi D, Tanaka C, Nakayama G, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Takeda S, Hayashi .
7. Tanabe KK, Goto H, Kodera Y. A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. *Onco Targets Ther* 2013; **6**: 1805-1812. [DOI: 10.2147/OTT.S53625]. eCollection 2013.
8. Li Y, Xie Q, Lu F, Zaho J, Mao P, Li Z, Liu S, Zhuang H. Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. *Liver Int* 2010; **30 (1)**: 112-118. DOI: 10.1111/j.1478-3231.2009.02134.x]
9. Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. *J Hepatol* 2010; **52 (6)**: 921-929. [DOI: 10.1016/j.jhep.2009.12.034]
10. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. *Oncogene* 2010; **29 (36)**: 4989-5005. [DOI: 10.1038/onc.2010.236]